China Medical System Holdings Limited (0867.HK)
| Previous close | 7.060 |
| Open | 7.050 |
| Bid | 7.000 x 0 |
| Ask | 7.010 x 0 |
| Day's range | 6.850 - 7.070 |
| 52-week range | 6.850 - 15.860 |
| Volume | |
| Avg. volume | 6,976,035 |
| Market cap | 17.084B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 6.60 |
| EPS (TTM) | 1.060 |
| Earnings date | 27 Mar 2024 |
| Forward dividend & yield | 0.43 (6.06%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | 13.26 |
- GlobeNewswire
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that on 31 March 2024, that the Group, through a
- GlobeNewswire
China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs
SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines were directly sold by the Group, the turnover would be RMB 9,472 million, a year-on-year decrease of 9.8%. Profit for the year was RMB2,384 million, and normalized profit for the year that excluding provisions of impairment losses
- GlobeNewswire
China Medical System (00867） Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®
SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned subsidiary entered into a Novation Agreement (the “Novation Agreement”) with Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and Winhealth Investment (HK) Limited (“Winhealth Investment”) for sucroferric oxyhydroxide chewable tablets Velphoro® (the “Product”). Winhealth Investment and VFMCRP en
